Ciencia y Tecnología
New diabetes drugs will be on the market, there are also weight loss prevention cardiovascular disease
[Technews Science and Technology News] Semaglutide is a GLP-1 analog (Note 1) newly developed by Novo Nordisk in Denmark, which will be used for the treatment of "type 2 diabetes". It is more than 90% similar to GLP-1, has a high stability in the human body, and can maintain it
